July 10, 2023
Artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. has been hit with a proposed shareholder class action accusing the company of failing to disclose stumbles that allegedly affected the integrity of a study of a drug for agitated seniors with dementia.